SANA (33) GLUE (27) MGTX (21) PRME (31) ⌘ Pro Terminal →

Ginkgo Bioworks Holdings Inc. (Class A) (DNA) — RQD Stock Rating Cockpit

$11.21 -12.01% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $10.95

Ginkgo Bioworks Holdings Inc. (Class A) (DNA) carries a Roarable Rating of D- (Sell) with 37/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (37/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D- • RED ALERT Cap $819.7M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on DNA Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is DNA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, Ginkgo Bioworks Holdings Inc. (Class A) (NYSE: DNA) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 37/100 at a spot price of $11.21 (-12.01% 1D, market cap $819.7M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 15/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 7/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, DNA ranks #605 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does DNA compare to SANA and GLUE in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), DNA carries a Roarable D- (37/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, SANA (Sana Biotechnology Inc.) holds a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $814.3M) and GLUE (Monte Rosa Therapeutics Inc.) posts a E grade (27/100 RQD, P/E N/A, ROIC -35.0%, cap $927.4M). Among the 5-stock peer group, DNA leads on earnings multiple (N/A) while DNA leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for DNA?

▼

Per DNA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001830214), Ginkgo Bioworks Holdings Inc. (Class A) generated $170.2M in revenue (-25.1% YoY), -$313.0K in net income, and -$178.7M in free cash flow against $1.12B in total assets and $0 in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $10.95 (-2.35%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (37/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.1% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk E

Each axis scored 0–20

12M PRICE TARGET CONE-9.5% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for DNA)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (37/100 Composite)

🔍 WHY DNA SCORES 37/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+15/20 pts (41% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▲ #2 Bullish Driver: Cash Engine Quality+7/20 pts (19% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$11.79-14.6% Next Q

Q2 (-2Q)

Grade D$10.07-0.5% Next Q

Q3 (-1Q)

Grade D$10.02+11.9% Next Q

Current

Grade D-$11.21-8.1% Hist 90D α

Trajectory: D (45) → D- (37)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a DNA Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While DNA currently carries a cautious 37/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Big institutional funds and options desks are actively positioning on the bullish side.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($9.65) and Max Pain ($11.77) forces dealer call-delta covering toward $19.13.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $DNA• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “DNA Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 37%NO 63%Trade / Inspect Odds →

RSI-14 MOMENTUMBULLISH MOMENTUM

58.430 Oversold · 70 Hot

ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)

3.80>3.0 Fortress Safe

PIOTROSKI F-SCOREWEAK QUALITY (1–4)

2 / 99-Pt Accounting

52-WEEK LASER RANGE45% OF RANGE

L: $5$11.21H: $18

1. Money & Cash Health● WEAK

Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: D-RQD 7 / 20

2. Big Money & Insiders● TRIMMING

Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: DRQD 18 / 40

3. Hidden Risks & Market Weather● WARNING

SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: ERQD 12 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

3-of-3 JEV AI Jury Bearish Warning on DNA

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

BEARISH (35)

-35.0% ROIC with 42.0% gross margin and -21.80% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

BEARISH (25)

Altman-Z 4.20 and Piotroski 2/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

BEARISH (42)

18/40 institutional & smart-money positioning score with 7/20 macro alignment.

Bull Case: Why Buyers Like DNA

✓Big institutional funds and options desks are actively positioning on the bullish side.

Bear Case: What Could Go Wrong

!Company executives have done more routine share selling than personal cash buying lately.
!Sensitive to high interest rates and tighter Federal Reserve market liquidity.
!Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring DNA)

✓Walkthrough of DNA's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

DNA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +13.12%📐 HORIZONTAL RANGE

2026-11-02O $13.32H $13.32L $11.21C $11.21VOL 2.90M

RES: $19.60SUP: $5.93SMA50: $9.65SMA200: $8.60

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

DNA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 DNA Butterfly Map → + Track DNA →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. -25.1% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on DNA today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for DNA. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for DNA today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (DNA)

Health Care Rank #605 of 1016 ⚔️ SANA vs DNA Full Matrix →

1. Head-to-Head Health Care Peer Comparison (DNA vs. SANA, GLUE, MGTX, PRME)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Ginkgo Bioworks Holdings Inc. (Class A) (DNA) ranks #605 by composite RQD confidence (37/100, grade D-) and #383 by equity capitalization ($819.7M). Within this direct 5-issuer industry benchmark cohort, DNA leads on earnings valuation at N/A trailing P/E, while DNA leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. DNA currently leads its immediate peer cohort in composite quantitative strength at 37/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
DNA ACTIVE Ginkgo Bioworks Holdings Inc. (Class A)	D-	37/100	—	—	-35.0%	-12.01%	$819.7M	Benchmark Subject
SANA Sana Biotechnology Inc.	E	33/100	—	—	-35.0%	-5.51%	$814.3M	/sana-vs-dna →
GLUE Monte Rosa Therapeutics Inc.	E	27/100	—	—	-35.0%	-1.01%	$927.4M	/glue-vs-dna →
MGTX MeiraGTx Holdings plc	E	21/100	—	—	-35.0%	-2.21%	$932.1M	/mgtx-vs-dna →
PRME Prime Medicine Inc.	E	31/100	—	—	-35.0%	-9.92%	$950.4M	/prme-vs-dna →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001830214

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Ginkgo Bioworks Holdings Inc. (Class A) (DNA) reported GAAP revenue of $170.2M (-25.1% vs. FY2024 revenue of $227.0M , and -32.3% cumulative change since FY2023) , GAAP net income of -$313.0K, operating cash flow of -$171.1M, and free cash flow of -$178.7M (+53.2% YoY). On the balance sheet, DNA closed FY2025 with $1.12B in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$170.2M	-$313.0K	-$171.1M	-$178.7M	$1.12B	—
FY2024 (FY)	2024-12-31	$227.0M	-$547.0K	-$319.6M	-$382.1M	$1.38B	—
FY2023 (FY)	2023-12-31	$251.5M	-$893.0K	-$295.5M	-$295.5M	—	—

3. DNA Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is DNA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does DNA compare to SANA and GLUE in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for DNA?

Where is DNA trading relative to its 50-day, 200-day, and 52-week technical levels?

DNA last traded at $11.21 (-12.01% on volume of 2,730,472 shares), positioning the stock +16.17% above its 50-day simple moving average ($9.65) and +30.35% above its 200-day simple moving average ($8.60). Across its 52-week range of $5.37 to $18.22, DNA sits at the 45.4% percentile with a 14-day RSI of 58.4 (BULLISH MOMENTUM) and an implied next-earnings move of ±12.5% ($9.81 to $12.61).

DNA Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell DNA stock right now?

Ginkgo Bioworks Holdings Inc. (Class A) (DNA) currently earns a Roarable Rating of D- (Sell — SELL) with 37/100 RQD Confidence. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.

What is DNA's 12-month price target and RQD AI Jury consensus?

DNA's 12-month base price target is $10.15 (range $7.92 to $19.13), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: DNA RQD Cockpit DNA 12M Forecast DNA Earnings & Move DNA Dividends & DRIP DNA Insiders & 13F DNA Whale Options DNA Profit Sankey DNA News & Why

ROARABLE RATING BRIEF • RQD 37/100 (D-) ✓ STAGE-C NUMBER FIREWALL VERIFIED

DNA — Ginkgo Bioworks Holdings Inc. (Class A): What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:32:38Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, DNA scores 37 out of 100 and receives a letter grade of D-, with the verdict label "Roarable Sell — Vulnerable Balance Sheet & Flow." The five pillars are:

Fundamental Cash Engine: 7 / 20. Per the Roarable RQD rating, this pillar reflects ROIC of -35% and an FCF yield of -21.8%. For a prospective investor, this indicates the business is currently consuming cash relative to its capital base rather than generating a cash return, which limits the valuation support available from current operations.
Whale 13F Flow: 15 / 20. Per the Roarable RQD rating, this pillar captures institutional accumulation and options positioning. This is the strongest pillar in the rating and suggests some institutional interest, though the source data does not break out the individual 13F holdings behind this score.
Insider Conviction: 3 / 20. Per the Roarable RQD rating, this pillar reflects SEC Form 4 and Congressional PTR cluster flow. The low score indicates insider flow provides limited confirmation of conviction in the stock.
Macro Regime Fit: 7 / 20. Per the Roarable RQD rating, the beta is 1.0 and the pillar reflects sector sensitivity. A beta of 1.0 means the stock is expected to move in line with the market, offering no defensive cushion in a downturn.
Forensic Balance Sheet: 5 / 20. Per the Roarable RQD rating, this pillar reflects an Altman Z-Score of 2.5, a Piotroski F-Score of 2/9, and a Debt/Equity ratio of 0.5. The weak Piotroski reading is the most notable balance-sheet-quality signal in the rating.

Taken together, the pillar scores point to fundamental and forensic weakness, partly offset by institutional flow. Upside drivers would need to come from a turnaround in cash generation, which the current ROIC and FCF yield do not yet show. Valuation tradeoffs are significant: with no reported EPS or P/E in the source data, the market is pricing the stock on factors the dataset does not fully quantify. This analysis is educational and not personalized financial advice.

Business

Per the profile, Ginkgo Bioworks Holdings Inc. (Class A) is a NYSE-listed issuer in the Health Care sector, within the Biotechnology: Biological Products (No Diagnostic Substances) industry. The source data does not describe its products, customers, or revenue model beyond the reported financials. Per the SEC financials, FY 2025 revenue was $170.2M, down from $227.0M in FY 2024, indicating the company generates revenue but at a declining rate across the reported periods.

Financial Trend

Period	Revenue	Operating Income	Net Income	EPS	FCF	Cash	Debt
FY 2025	$170.2M	$-315.3M	$-0.3M	N/A	$-178.7M	$167.2M	N/A
FY 2024	$227.0M	$-559.8M	$-0.5M	N/A	$-382.1M	$561.6M	N/A
FY 2023	$251.5M	$-864.4M	$-0.9M	N/A	$-295.5M	N/A	N/A

Per the SEC financials, operating losses narrowed from $-864.4M in FY 2023 to $-315.3M in FY 2025, though operating margin remains at -60% per the market data. Per the market data, net margin is -0.2% and gross margin is 0%. ROIC is -35% per the market data. The Roarable RQD rating reports an Altman Z-Score of 2.5, a Piotroski F-Score of 2/9, and a Debt/Equity ratio of 0.5. Per the SEC financials, cash declined from $561.6M in FY 2024 to $167.2M in FY 2025, a reduction that is consistent with the negative free cash flow reported in both years.

Recent Catalysts & News Wire Analysis

Per the news feed, the recent coverage includes a Yahoo Finance report on analysts reassessing AI demand (classified YELLOW), a Benzinga report on Friday stock movement (YELLOW), and a Seeking Alpha report stating that the valuation has outrun the business (YELLOW). A Yahoo Finance report on a market-uptick decline was flagged as RISK WATCH (RED). Per the news feed, CFO Steven Coen sold $7,769 of company stock, per an Investing.com report. A Motley Fool report describes a deal with Eli Lilly followed by a share price doubling. The Butterfly Supply-Chain Graph contains no supply-chain links or proprietary signals.

Butterfly Effect: 2nd-Order Supply-Chain & Sector Ripples

Per the Butterfly Supply-Chain Graph, the supply chain is listed as NONE, with no butterfly links and no proprietary signals. Upstream and downstream dependencies, sector correlations, and second-order bottlenecks are therefore not available in source data. Investors should note that the news feed references an Eli Lilly deal, which would imply a downstream commercial relationship, but the source data does not establish its terms or scale.

Open Questions

What are the company's products and revenue sources, given that revenue fell from $227.0M to $170.2M between FY 2024 and FY 2025?
What is the status and size of the Eli Lilly arrangement referenced in the news feed, and does it affect future revenue?
What drove the cash decline from $561.6M to $167.2M, and what is the remaining runway at the reported negative free cash flow?
Why are EPS, P/E, forward P/E, and EV/EBITDA unavailable, and how should the valuation be assessed without them?
What are the institutional 13F holdings and options positioning behind the whale flow score of 15 / 20?

DNA Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Ginkgo Bioworks Holdings Inc. (Class A) (DNA) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to DNA Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo Finance • 14h ago

Ginkgo Bioworks (DNA) Stock Fair Value Edges Higher After Analysts Reassess AI Demand

Yahoo Finance report covering Ginkgo Bioworks Holdings Inc. (Class A) (DNA) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Benzinga • 17h ago

What's Going on With Ginkgo Bioworks Stock on Friday? - Ginkgo Bioworks Holdings (NYSE:DNA)

Benzinga report covering Ginkgo Bioworks Holdings Inc. (Class A) (DNA) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Seeking Alpha • 20h ago

Ginkgo Bioworks: The Valuation Has Outrun The Business (NYSE:DNA)

Seeking Alpha report covering Ginkgo Bioworks Holdings Inc. (Class A) (DNA) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH Yahoo Finance • 23h ago

Ginkgo Bioworks Holdings, Inc. (DNA) Stock Falls Amid Market Uptick: What Investors Need to Know

Yahoo Finance report covering Ginkgo Bioworks Holdings Inc. (Class A) (DNA) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Investing.com • 1d ago

Ginkgo Bioworks CFO Steven Coen sells $7,769 of company stock

Investing.com report covering Ginkgo Bioworks Holdings Inc. (Class A) (DNA) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE The Motley Fool • 1d ago

This Small-Cap Stock Announced a Deal With Eli Lilly. Then Its Shares Doubled

The Motley Fool report covering Ginkgo Bioworks Holdings Inc. (Class A) (DNA) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 1d ago

Ginkgo Bioworks Holdings, Inc. Estimates – NYSE:DNA

TradingView report covering Ginkgo Bioworks Holdings Inc. (Class A) (DNA) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 1d ago

Officer Steven P. Coen proposes selling 2,403 Ginkgo Bioworks (NYSE: DNA) shares.

Stock Titan report covering Ginkgo Bioworks Holdings Inc. (Class A) (DNA) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

DNA Bull vs. Bear Conversation Board — What's Your Call at $11.21?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON DNA 🐻 67% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $11.21 (-12.0%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is DNA (D- • RQD 37/100) a Buy at $12.74?

Welcome to the DNA (Ginkgo Bioworks Holdings Inc. (Class A)) Roar Pit. Current RQD Composite is 37/100 (Roarable Sell — Vulnerable Balance Sheet & Flow) in Biotechnology: Biological Products (No Diagnostic Substances). Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

FO ForensicBear Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $9.56 (-25.0%)

Spot @ $12.74

Pump the brakes on DNA — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on DNA, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Ginkgo Bioworks Holdings Inc. (Class A) expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

DE DeltaGamma_99 Verified K Arena Trader 🐂 BULLISH 🎯 Target: $16.31 (+28.0%)

Spot @ $12.74

DNA cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on DNA, the market is fixating on short-term headline noise in Biotechnology: Biological Products (No Diagnostic Substances) and ignoring the balance sheet and cash flow trajectory. At $12.74 (52-wk range $5.37 - $18.22), any beat on forward guidance forces shorts and underweight funds to chase.